by Lupus, also known as systemic lupus erythematosus or SLE, is an autoimmune disease where the immune system attacks healthy cells and tissues in different parts of the body causing inflammation and tissue damage. The most common symptoms of lupus include fatigue, joint pain, rash, and photosensitivity. If left untreated, lupus can damage organs like kidneys, heart, lungs etc. Currently, there is no cure for lupus and treatment mainly focuses on managing symptoms and preventing organ damage. The global lupus therapeutic market consists of drugs for treating different complications of lupus like nonsteroidal anti-inflammatory drugs, anti-malarials, corticosteroids, immunosuppressive drugs. These drugs help reduce inflammation, treat infections and suppress the immune system. Growing prevalence of lupus worldwide along with rising awareness about its effective management is expected to drive the demand for lupus therapeutic drugs over the forecast period.
The global Lupus Therapeutic Market is estimated to be valued at US$ 30 billion in 2023 and is expected to exhibit a CAGR of 5.6% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
A key trend witnessed in the global lupus therapeutic market is the rising focus on development of novel biologics for improved treatment outcomes. Currently approved biologic drugs like belimumab have shown promise in controlling disease symptoms with lesser side effects compared to conventional drugs. This has prompted research into monoclonal antibodies, fusion proteins, therapeutic vaccines and gene therapies. Ongoing clinical trials of these novel biologics aims to induce long term remission, reverse organ damage and achieve cure in difficult to treat lupus patients. Their successful development and approval will reshape the lupus treatment landscape going forward.
Porter’s Analysis
Threat of new entrants: The threat of new entrants in lupus therapeutic market is moderate as significant R&D investments and clinical trials are required to gain regulatory approvals for new drugs.
Bargaining power of buyers: The bargaining power of buyers is moderate as few large pharmaceutical companies dominate the global market.
Bargaining power of suppliers: The bargaining power of suppliers is low as companies procure generic raw materials from various suppliers globally.
Threat of new substitutes: The threat of new substitutes is high as new innovative biologics and drugs are emerging for treating lupus.
Competitive rivalry: The competitive rivalry in the market is high due to presence of many global and regional players.
Key Takeaways
The Global Lupus Therapeutic Market Demand is expected to witness high growth.
Regional analysis: North America is expected to maintain its dominance during the forecast period. This is attributed to the rising prevalence of lupus in the U.S., favorable reimbursement policies, and approval of new drugs in the region. Asia Pacific is anticipated to exhibit fastest growth owing to growing geriatric population and increasing approval of cost-effective biosimilars.
Key players: Key players operating in the lupus therapeutic market are GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd, Pfizer Inc, AstraZeneca, Bristol-Myers Squibb, Anthera Pharmaceuticals Inc, ImmuPharma PLC. AbbVie focuses on developing novel therapies to treat lupus and other autoimmune diseases.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
